

February 13, 2024

Company Name Otsuka Holdings Co., Ltd.  
 Name of Representative Tatsuo Higuchi  
 President and Representative Director, CEO  
 Code Number 4578, Prime market of the Tokyo Stock  
 Exchange  
 Contact Yuji Kogure  
 Director, Investor Relations Department  
 (Phone: +81-3-6361-7411)

## Notice Regarding Revisions of Consolidated Results Forecast for FY2023

Based on our recent business results, Otsuka Holdings Co., Ltd. (the “Company”) hereby revised our consolidated financial forecasts of FY2023 previously announced on October 31, 2023.

### 1. Revision of the consolidated financial forecasts for the Fiscal Year Ended December 31, 2023

	Revenue	Business profit	Operating profit	Profit before tax	Profit for the period	Profit attributable to owners of the Company	Basic earnings per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous forecast(A)	1,985,000	300,000	245,000	250,000	192,000	188,000	346.44
Revised forecast(B)	2,018,000	312,000	139,000	142,000	125,000	121,000	222.97
Amount of change(B-A)	33,000	12,000	▲106,000	▲108,000	▲67,000	▲67,000	
Change (%)	1.7%	4.0%	▲43.3%	▲43.2%	▲34.9%	▲35.6%	
(Reference) Consolidated results of FY2022	1,737,998	174,917	150,323	172,954	137,280	133,906	246.80

Note:

Due to the application of IAS 12 “Income Taxes” (amended in May 2021), results for the year ended December 31, 2022, have been retrospectively restated.

### 2. Reasons for the revision

Sales revenue in all business remained strong for the consolidated fiscal year. In particular, for pharmaceutical business the long acting antipsychotic agent *ABILIFY MAINTENA*, the antipsychotic agent *REXULTI/RXULTI*, the V<sub>2</sub>-receptor antagonist *JINARC/JYNARQUE*, the anti-cancer agent *LONSURF* four global products, as well as the nutraceuticals business led the business performance, and even excluding the impact of foreign exchange, the business remained above plan. On the other hand, in the fourth quarter of this fiscal year, the Company expects to record an impairment loss of approximately ¥115 billion in AVP-786, which is under development for the agitation associated with dementia due to Alzheimer's disease, as well as in

other businesses. As a result, operating income, profit for the period and profit attributable to owners of the company are expected to be lower than previously announced estimates.

The consolidated financial results for the fiscal year ending December 2023 and the consolidated financial results forecast for the fiscal year ending December 2024 are scheduled to be announced when the financial results are announced on February 14, 2024.

Note:

The above forecasts are based on information available and certain assumptions that the Company deems reasonable at the time of the announcement. Actual operating results may differ from these projections due to various factors.